Navigation Links
3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
Date:11/21/2013

MENLO PARK, Calif., Nov. 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc. (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical Officer.  Dr. McCulloch brings nearly three decades of senior research and development experience to 3-V, including an extensive preclinical and clinical development background in oncology.  Dr. McCulloch will be responsible for 3-V's clinical, medical affairs and regulatory functions, overseeing strategy and implementation for the advancement of 3-V's pipeline of proprietary therapeutic candidates. 

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"With a thorough understanding of the oncology field and many years of relevant experience in the pharmaceutical and biotech industries, Bill brings significant breadth and depth to our executive team," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  "Bill will provide invaluable leadership as we move forward in the clinical evaluation of our lead FASN inhibitor in patients with solid tumors."

"I look forward to leading the development of TVB-2640, a promising fatty acid synthase inhibitor, through clinical development. Our first study will explore safety, dosing levels and initial anti-cancer activity in patients with advanced solid tumors," said Dr. McCulloch.  "I was attracted to this position based on the potential of TVB-2640, as well as 3-V's wealth of opportunity based on its drug discovery capabilities, leadership team and backing from top venture capital firms."

Dr. McCulloch previously served as Chief Medical Officer at Gloucester Pharmaceuticals, Inc., where he led the regulatory strategy and oversaw the conduct of the pivotal trial that led to approval by the U.S. Food and Drug Administration of their HDAC inhibitor romidepsin (Istodax®) in November 2009 and the subsequent acquisition of Gloucester by Celgene Corporation in January 2010.  He also served as an Executive Vice President and Medical Director at Pappas Ventures, lending his clinical and medical expertise to their portfolio companies.  Dr. McCulloch has worked for large pharmaceutical companies Bristol-Myers and Astra AB, start-up companies U.S. Bioscience and Sparta Pharmaceuticals, and most recently has served as President of Alba BioPharm Advisors, Inc.   He has undertaken all phases of drug and technology development and has been directly involved in the U.S. and Europe in filing INDs/CTAs and NDAs/MAAs, with their requisite face-to-face regulatory meetings, securing orphan drug status for compounds and obtaining SBIR and other grant funding for his projects.  Dr. McCulloch practiced medicine for seven years in the U.K., including post-graduate training in Internal Medicine, Hematology and Oncology, before joining the international pharmaceutical industry in 1984.  He holds a medical degree (M.B., Ch.B.) from the University of Glasgow in Scotland, is a Fellow of the Royal College of Physicians of Glasgow and is also a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.

About FASN Inhibition
FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers.  In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers.  Single-agent and combinations of 3-V FASN inhibitors have both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts.

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease.  In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis.  3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact Information
Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries
BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
Breaking Medicine News(10 mins):